REPLY: Spike Reply and Storm Reply Achieve AWS Security Competency Status
Reply announced today that its companies Storm Reply and Spike Reply achieved Amazon Web Services (AWS) Security Competency status. This designation recognizes that the two companies of the Reply Group have demonstrated deep expertise that helps customers achieve their cloud security goals.
Achieving the AWS Security Competency differentiates Storm Reply and Spike Reply as AWS Partner Network (APN) members that provide specialized consultancy services and integrated solutions designed to help enterprises adopt, develop and deploy complex security projects on AWS. To receive the designation, APN Partners must possess deep AWS expertise and deliver solutions seamlessly on AWS.
Filippo Rizzante, CTO Reply, commented: “We are proud to be among the first APN partners to achieve AWS Security Competency status. This AWS competency status confirms the ability of our teams in helping companies achieve their security goals by combining our expertise with the range of powerful security tools that AWS provides”.
Respectively, Storm Reply and Spike Reply have a deep expertise in supporting companies worldwide in the implementation of Cloud-based systems and applications and in the deployment of integrated solutions for business security.
AWS is enabling scalable, flexible, and cost-effective solutions from start-ups to global enterprises. To support the seamless integration and deployment of these solutions, AWS established the AWS Competency Program to help customers identify Consulting and Technology APN Partners with deep industry experience and expertise.
As APN Premier Consulting Partner, Reply helps customers wishing to enhance their security posture by leveraging on cloud-based solutions and services that allow to develop effective cyber risk management programs.
Spike Reply
Spike Reply specialises on Cyber Security, Personal Data protection and tailored Managed Security Services. Spike Reply Cyber Security services range from helping customer to develop an effective cyber risk management program, in line with the strategic objectives and risk appetite of the organization, to the planning, design and implementation of all the corresponding technological, legal, organizational, underwriting and risk-limiting countermeasures. With a broad network of partnerships, Spike Reply select the most appropriate security solutions and helps organizations to improve their cyber response capabilities through its advanced threat simulation. www.reply.com
Storm Reply
Storm Reply is the Reply Group Company specializing in design and implementation of cloud-based solutions and services. Storm Reply holds Amazon Premier Consulting Partner Status since 2014 and helped a large number of relevant customers in Europe to run their systems and applications on the AWS Platform. Having a consolidated experience in Cloud IaaS, PaaS and SaaS architectures, Storm Reply provides an end to end set of services for Cloud Adoption, Development of new applications and management full services of their cloud environment. Having deep competencies and experiences on management of complex cloud projects, Storm Reply helps customers to implement their Strategy Cloud Approach. In particular, Storm Reply offers services on Cloud Strategy and Migration, Cloud Native Applications development and Cloud Service Management. www.storm.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210128005036/en/
Contact information
Media
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Aaron Miani
a.miani@reply.com
Tel. +3902535761
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release
The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom